

Inhaltsverzeichnis

	Note
§ 1 Personalstatut natürlicher Personen	36
I. Grundproblematik	36
1. Begriff des Personalstatuts	36
2. Staatsangehörigkeits- oder Wohnsitzprinzip	38
a) Altes IPR	39
b) 1865 bis ca. 1956	41
c) 1956 bis 1997	44
d) Seit 1997	46
e) Résumé	48
II. Rechtsquellen	49
III. Europäische Union	50
IV. Schweiz	51
1. Überblick	51
2. Natürliche Personen	52
a) Wohnsitz	53
b) Gewöhnlicher Aufenthalt	55
aa) IPRG	56
bb) Multilaterale Staatsverträge	60
cc) Bilaterale Abkommen	62
c) Staatsangehörigkeit	63
3. Mehrstaater	65
a) Grundlagen und Regelung	65
b) Effektive Staatsangehörigkeit	69
4. Staatenlose	71
a) Begriff	72
b) Statut	74
5. Flüchtlinge	75
a) Begriff	76
b) Statut	77
V. Konflikte mit ausländischem Recht	78
1. Recht der EU-Mitgliedstaaten	78
2. Weltweite Konflikte	79
a) Religionszugehörigkeit	80
b) Stammesrecht	82
c) Kasten-Zugehörigkeit	84
d) Résumé	85
§ 2 Rechts- und Handlungsfähigkeit, Geschlecht	86
I. Grundproblematik	86
II. Rechtsquellen	87
III. Europäische Union	88
IV. Schweiz	90
1. Rechtsfähigkeit	90

	Note
a) Geburt	91
b) Altersfeststellung	92
c) Tod	93
d) Résumé	94
2. Handlungsfähigkeit	95
a) Allgemeine Handlungsfähigkeit	96
aa) Renvoi	96
bb) Statutenwechsel	99
cc) Beschränkte Handlungsfähigkeit Minderjähriger	101
b) Besondere Handlungsfähigkeiten	103
3. Geschlechtszugehörigkeit	104
a) Zuständigkeit	106
b) Anwendbares Recht	107
c) Anerkennung ausländischer Geschlechtsänderungen	108
4. Partei- und Prozessfähigkeit	109
V. Konflikte mit ausländischem Recht	110
1. Recht der EU-Mitgliedstaaten	110
2. Weltweite Konflikte	111
§ 3 Name	112
I. Grundproblematik	112
II. Rechtsquellen	114
III. Europäische Union	115
1. Gesetzlicher Name	115
a) Rechtsprechung des EuGH	115
b) Bedeutung	122
2. Namensänderung	124
3. Namensregistrierung	125
IV. Schweiz	126
1. Gesetzlicher Name	126
a) Wohnsitzprinzip	127
b) Renvoi	129
c) Rechtswahl	131
d) Statutenwechsel	134
2. Namensänderung	135
a) Allgemeines	135
b) Zuständigkeit	136
c) Anwendbares Recht	137
d) Anerkennung ausländischer Namensänderungen	138
3. Namensregistrierung	140
a) Gesetzlicher Name	141
b) Transkription	143
c) Middle Names	144
d) Unterschied nach Geschlecht	145
4. Konflikte mit ausländischem Recht	147
a) Europäische Union	147
b) Weltweite Konflikte	149

	Note
§ 4 Erwachsenenschutz	151
I. Grundproblematik	151
II. Rechtsquellen	153
III. Europäische Union	154
IV. Schweiz	155
1. Anwendungsbereich des HESÜ	155
a) Allgemeines	155
b) Persönlicher Anwendungsbereich	156
c) Sachlicher Anwendungsbereich	157
2. Internationale Zuständigkeit nach dem HESÜ	159
a) Primär- und Allzuständigkeit: Aufenthaltsbehörden	159
b) Sekundäre Zuständigkeiten	161
aa) Auftragszuständigkeit	161
bb) Subsidiäre Heimat- und Belegenheitszuständigkeit	162
c) Eilzuständigkeit	164
d) Zuständigkeit für einstweilige Anordnungen	165
e) Koordinierung	166
3. Anwendbares Recht nach dem HESÜ	167
a) Grundsatz	167
aa) Lex fori in foro proprio	167
bb) Ausnahme: Ausländisches Recht	168
b) Vorsorgeauftrag	170
aa) Anwendbares Recht	171
bb) Abänderbarkeit	173
c) Schutz Dritter	174
4. Anerkennung und Vollstreckung	175
5. Zusammenarbeit der Behörden	177
V. Konflikte mit ausländischem Recht	178
1. Europäische Union	178
2. Weltweite Konflikte	179
§ 5 Verschollenheit	180
I. Grundproblematik	180
II. Rechtsquellen	182
III. Europäische Union	183
1. Zuständigkeit	183
2. Anwendbares Recht	184
3. Anerkennung ausländischer Verschollenerklärungen	185
IV. Schweiz	186
1. Zuständigkeit	186
a) Normale Zuständigkeit	187
b) Ausserordentliche Zuständigkeit	188
2. Anwendbares Recht	190
3. Anerkennung ausländischer Verschollenerklärungen	191
4. Konflikte mit ausländischem Recht	192
a) Europäische Union	192
b) Weltweite Konflikte	193

Inhalt

Vorwort	7
LUCIEN CRIBLEZ, CHRISTINA ROTHEN, THOMAS RUOSS	

Der Wandel von Staatlichkeit in der Schweiz aus interdisziplinärer Perspektive. Zur Einleitung	11
THOMAS RUOSS, CHRISTINA ROTHEN, LUCIEN CRIBLEZ	

Staatlichkeit als Praxis

Vermarktlichung des Gemeinnützigen? Neuordnungen des <i>public-private mix</i> in der Altersvorsorge Ende des 20. Jahrhunderts	31
MATTHIAS RUOSS	

Entwicklungshilfe im Innern. Die Heimpolitik des Bundes im Zeichen sich wandelnder Staatlichkeit, 1960–1990	57
URS GERMANN	

Der moderne Gesellschafts- und Bundesvertrag. Steuerpolitik im Kontext von sozioökonomischem Wandel und föderalistischer Staatlichkeit	85
GISELA HÜRLIMANN	

Expertenempfehlungen und politische Zielsetzungen. Zu den Diskussionen um einen Verfassungsartikel für Konjunkturpolitik Anfang der 1970er-Jahre	115
SIMONE CHIQUET	

Rechenschaft, Planung, Information. Prozesse, Formen und Inhalte der Luzerner Staatsverwaltungsberichte	143
FLAVIAN IMLIG	

Kontingentierung von Migration. Zur Soziologie einer Regierungstechnik	171
MICHAEL MÜLLI	

Transformationen des Gesundheitswesens seit den 1960er-Jahren. Die Beispiele der Aids- und der Drogenthematik	193
PETER-PAUL BÄNZIGER	

Transformationen durch Wissen und Bildung

- Sanfter Etatismus. Weiterbildungspolitik in der Schweiz 219
MICHAEL GEISS
- Bundesstaatliche Förderung und föderalistische Verantwortung. Zur
Neuregelung der Stipendienpolitik in den 1960er- und 1970er-Jahren 247
LUCIEN CRIBLEZ
- Eine neue Politik für eine neue Generation. Zum Wandel des Politikfelds
Jugend in der Schweiz, 1960–1980 271
RAHEL BÜHLER
- Zwischen Innovation und Administration. Genese der wissenschaftlich
orientierten Bildungsplanung in Zürich, Bern und Neuenburg, 1960–1990 297
CHRISTINA ROTHEN
- Viel Diskurs – wenig Steuerung. Schweizer Wissenschaftspolitik in der
Mehrebenenrealität 317
THOMAS GEES
- Der Talent-Turn und seine staatliche Begleitmusik. Migration und
die Politik der Hochqualifizierung 341
GANGA JEY ARATNAM

Diskussion und Ausblick

- Gab es in der Schweiz eine neoliberale Wende? Ein Kommentar 369
DANIEL SPEICH CHASSÉ
- Die Transformation von Staatlichkeit in der Schweiz 1960–1990 aus
bildungshistorischer Perspektive 385
LUCIEN CRIBLEZ
- Wandel von Staatlichkeit in der Schweiz in der zweiten Hälfte des
20. Jahrhunderts. Eine politikwissenschaftliche Perspektive 403
THOMAS WIDMER
- Autorinnen und Autoren 419

Contents

1 Introduction	1
Definitions	1
Historical Aspects of Biomarkers	2
Classification of Biomarkers	3
Biological Marker as Response to Therapeutic Intervention	3
Pharmacokinetic/Pharmacodynamics Biomarkers	4
Predictive Biomarkers	4
Valid Biomarkers	5
Types of Biomarkers	5
Genes as Biomarkers	6
Proteins as Biomarkers	6
Proteomics	7
DNA Biomarkers	7
Mitochondrial DNA	7
Mitochondrial Mutations	8
RNA Biomarkers	8
Transcriptomics	9
MicroRNAs	10
Metabolomics	10
Glycomics	11
Single-Nucleotide Polymorphisms	12
Haplotyping	12
Cell Biomarkers of Disease	13
Stem Cell Biomarkers	13
Cancer Stem Cell Biomarkers	14
Endoglin as a Functional Biomarker of Stem Cells	14
p75NTR as a Biomarker to Isolate Adipose Tissue-Derived Stem Cells	15
Protein Expression Profile as Biomarker of Stem Cells	15
STEMPRO® EZChek™ for Analysis of Biomarkers of hESCs	15
SSEA-4 as Biomarker of MSCs	16
Autoantibodies as Biomarkers of Autoimmune Diseases	16

The Ideal Biomarker	17
Biomarkers and Systems Biology	18
Systems Biology Approach to Biomarker Identification	19
Relation of Biomarkers to Other Technologies and Health care	20
Biomarkers and Translational Medicine	20
Limitations of Use of Biomarkers in Health Care	20
2 Technologies for Discovery of Biomarkers	23
Introduction	23
Detection of Biomarkers in Tissues and Body Fluids	23
Disease Biomarkers in Breath	23
Portable Breath Test for Volatile Organic Compounds	24
Detection of Breath Biomarkers by Sensation Technology	24
Detection of Breath Biomarkers Optical Frequency	
Comb Spectroscopy	25
Genomic Technologies	25
Gene Expression	25
Tissue Microarrays for Study of Biomarkers	28
Epigenomic Technologies	28
Discovery of Methylation Biomarkers	29
Proteomic Technologies	30
2D GE	31
Isotope-Coded Affinity Tags	32
Mass Spectrometry	33
Liquid Chromatography-MS Combination	37
Protein Tomography	37
Protein Biochips/Microarrays and Biomarkers	38
Real-Time PCR for Quantification of Protein Biomarkers	39
Magnetic Beads for Protein Biomarker Discovery	40
CellCarta [®] Proteomics Platform	40
MASstermind TM	41
Search for Biomarkers in Body Fluids	41
Challenges and Strategies for Discovery of Protein	
Biomarkers in Plasma	41
Biomarkers in the Urinary Proteome	47
Peptides in Body Fluids and Tissues as Biomarkers of Disease	47
Verification for Interlaboratory Reproducibility of Protein	
Biomarkers	49
Significance of Similar Protein Biomarkers in Different Tissues	50
Glycomic Technologies	51
Metabolomic Technologies	51
Mass Spectrometry-Based Kits for Discovery of Metabolic	
Biomarkers in Plasma	52
Urinary Profiling by Capillary Electrophoresis	52
Lipid Profiling	53

Role of Metabolomics in Biomarker Identification	
and Pattern Recognition	53
Validation of Biomarkers in Large-Scale Human	
Metabolomics Studies	54
Lipidomics	54
Fluorescent Indicators for Biomarkers	55
Molecular Imaging Technologies	56
Computer Tomography	56
Magnetic Resonance Imaging	57
Positron Emission Tomography	57
Advantages of Imaging Biomarkers	58
Monitoring In Vivo Gene Expression by Molecular Imaging	58
Molecular Imaging In Vivo as a Biomarker	59
Challenges and Future Prospects of Molecular Imaging	59
Molecular Imaging in Clinical Practice	60
Nuclear Magnetic Resonance	61
Chemical Derivatization to Enhance Biomarker Detection	
by NMR	61
Fluxomics by Using NMR	62
Nanobiotechnology	62
Nanomaterials for Biolabeling	63
Nanoproteomics and Biomarkers	65
Nanoparticles for Molecular Imaging	66
Nanoparticles for Discovering Biomarkers	67
Nucleoprotein Nanodevices for Detection of Cancer Biomarkers	67
Future Prospects of Application of Nanobiotechnology	
for Biomarkers	67
Bioinformatics	68
Biomarker Workflow Guide	68
Analysis of Microarray Data for Selecting Useful Biomarkers	68
Role of Bioinformatics in Discovery of Proteomic Biomarkers	69
Role of Bioinformatics in Detection of Cancer Biomarkers	70
Biomarker Databases	70
Gene Networks as Biomarkers	71
Pitfalls in the Discovery and Development of Biomarkers	71
3 Biomarkers and Molecular Diagnostics	73
Introduction	73
Molecular Diagnostic Technologies	73
Polymerase Chain Reaction	73
Combined PCR-ELISA	75
Non-PCR Methods	76
Transcription-Mediated Amplification	77
Rapid Analysis of Gene Expression	77
WAVE Nucleic Acid Fragment Analysis System	77

DNA Probes with Conjugated Minor Groove Binder	78
Rolling-Circle Amplification Technology	79
Circle-to-Circle Amplification	81
Biochips and Microarrays	81
Detection and Expression Profiling of miRNA	83
Real-Time PCR for Expression Profiling of miRNAs	83
Use of LNA to Explore miRNA	84
Microarrays for Analysis of miRNA Gene Expression	84
4 Biomarkers for Drug Discovery and Development	87
Introduction	87
Biomarker Technologies for Drug Discovery	88
Proteomics-Based Biomarkers for Drug Discovery	88
Chemoproteomics	89
Transcriptomics for Drug Discovery	89
Metabolomics for Drug Discovery	90
Biomarkers and Drug Safety	91
Biomarkers of Adverse Drug Reactions	91
Applications of Biomarkers in Drug Safety Studies	91
Genomic Technologies for Toxicology Biomarkers	92
Proteomic Technologies for Toxicology Biomarkers	93
Metabonomic Technologies for Toxicology Biomarkers	93
Integration of Genomic and Metabonomic Data to Develop Toxicity Biomarkers	94
Toxicology Studies Based on Biomarkers	94
Applications of Biomarkers for Drug Development	99
Application of Metabonomics/Metabolomics for Drug Development	99
Role of Pharmacokinetic/Pharmacodynamic Biomarkers in Drug Development	100
Molecular Imaging as a Biomarker in Drug Development	101
Biomarkers in Clinical Trials	105
Application of Biomarkers by the Pharmaceutical Companies	108
Drug Development in Cardiovascular Disorders	109
Drug Development in Neurological Disorders	109
Future Prospects of Biomarker-Based Drug Development	110
5 Role of Biomarkers in Health Care	115
Introduction	115
Biomarkers of Inflammation	116
Biomarkers of Oxidative Stress	116
Oxidative DNA Damage	116
Proteins as Biomarkers of Oxidative Stress in Diseases	117
1,4-Dihydroxynonane Mercapturic Acid	117
Biomarkers in Metabolic Disorders	117

Biomarkers of Acute Intermittent Porphyria	117
Liver X Receptors	118
Biomarkers of Diabetes Mellitus	118
Biomarkers of Metabolic Syndrome	122
Biomarkers in Immune Disorders	123
Biomarkers of Failure of Transplanted Organs	123
Systemic Lupus Erythematosus	126
Biomarkers of Musculoskeletal Disorders	129
Biomarkers of Rheumatoid Arthritis	129
Biomarkers of Spondylarthritis	130
Biomarkers of Osteoarthritis	131
Biomarkers of Osteoporosis	132
Dual X-Ray Absorptiometry	133
Bone Imaging with Quantitative CT and MRI	133
Assays for Detection of Biomarkers of Osteoporosis	134
Biomarkers of Infectious Diseases	134
Application of Proteomics for Discovering Biomarkers of Infections	137
Systemic Inflammatory Response Syndrome	138
Tuberculosis	138
Biomarkers of Viral Infections	141
Biomarkers in Parasitic Infections	145
Biomarkers of Liver Disease	147
Breath Biomarkers of Liver Disease	147
Biomarkers of Viral Hepatitis B and C	148
Biomarkers of Liver Injury	149
Biomarkers of Liver Cirrhosis	149
FibroMax	149
Biomarkers of Pancreatitis	150
Biomarkers of Renal Disease	150
Cystatin C as Biomarker of Glomerular Filtration Rate	151
Proteomic Biomarkers of Acute Kidney Injury	151
Biomarkers of Lupus Nephritis	152
Biomarkers of Diabetic Nephropathy	152
Biomarkers of Pulmonary Diseases	152
Biomarkers of Oxidative Stress in Lung Diseases	154
Biomarkers of Survival in Acute Respiratory Distress Syndrome	154
Pulmonary Surfactant Proteins as Biomarkers for Lung Diseases	155
Biomarkers of Chronic Obstructive Pulmonary Disease	156
Biomarkers of Asthma	158
Biomarkers for Cystic Fibrosis	161
Biomarkers of Pulmonary Embolism	162
Biomarkers in Obstetrics and Gynecology	163
Biomarkers for Preeclampsia	163
Biomarkers of Premature Birth	166

Biomarkers of Oxidative Stress in Complicated Pregnancies	167
Biomarkers of Premenstrual Dysphoric Disorder	167
Biomarkers of Endometriosis	168
Fetal Biomarkers in Maternal Blood	168
Biomarkers for Genetic Disorders	169
Biomarkers for Down's Syndrome	169
Biomarkers for Muscular Dystrophy	170
Biomarkers of Phenylketonuria	170
Biomarkers of Lysosomal Storage Disorders	171
Biomarkers of Aging	173
Study of Biomarkers of Aging in a Genetically Homogeneous Population	174
Genes as Biomarkers of Aging	174
Role of Bioinformatics in Search for Biomarkers of Aging	176
Effect of Calorie Restriction on Biomarkers of Longevity	176
Biomarkers of Miscellaneous Disorders	176
Biomarkers of Inflammatory Bowel Disease	176
Biomarkers of Erectile Dysfunction	177
Biomarkers of Heat Stroke	178
Biomarkers of Pain	179
Nasal Nitric Oxide as a Biomarker of Response to Rhinosinusitis Therapy	180
Biomarkers Common to Multiple Diseases	181
Biomarkers and Nutrition	182
Biomarkers in Nutritional Epidemiology	182
Biomarkers of Nutritional Status	182
Biomarkers of Branched-Chain Amino Acid Status	183
Biomarkers of Caloric Restriction	183
Biomarkers of Malnutrition	184
Proteomic Biomarkers and Nutrition	184
Biomarkers of Gene-Environmental Interactions in Human Disease .	184
Future Role of Biomarkers in Health Care	185
Applications of Biomarkers Beyond Health Care	186
Combating Bioterrorism	186
Biomarkers for Monitoring Human Exposure to Environmental Toxins	186
Application of Biomarkers in Animal Health	187
6 Biomarkers of Cancer	189
Introduction	189
The Ideal Biomarker for Cancer	189
Single Versus Multiple Biomarkers of Cancer	190
Types of Cancer Biomarkers	191
miRNAs as Biomarkers in Cancer	192
Biomarkers of Epigenetic Gene Silencing in Cancer	195

Immunologic Biomarkers of Cancer	196
Molecular Diagnostic Techniques for Cancer	196
Technologies for Detection of Cancer Biomarkers	197
Genomic Technologies for Cancer Biomarkers	197
Tissue Microarrays for Study of Cancer Biomarkers	202
Molecular Fingerprinting of Cancer	203
Biomarkers of Inflammation in Cancer	204
Proteomic Technologies for Detecting Biomarkers of Cancer . . .	205
Metabolomic Biomarkers of Cancer	215
Epitomics for the Early Detection of Cancer	217
Detection of Biomarkers of DNA Methylation	217
Nanobiotechnology for Early Detection of Cancer to Improve Treatment	222
Selective Expression of Biomarkers by Cancer Compared with Normal Tissues	223
Ultrasound Radiation to Enhance Release of a Tumor Biomarker .	223
In Vivo Imaging of Cancer Biomarkers	224
Kallikrein Gene Family and Cancer Biomarkers	226
Circulating Cancer Cells in Blood as Biomarkers of Cancer	226
Applications of Cancer Biomarkers	227
Use of Biomarkers for Cancer Classification	228
Use of Biomarkers for Early Detection of Cancer	228
Application of Biomarkers for Cancer Diagnosis	229
Applications of Biomarkers for Cancer Diagnosis Plus Therapy . .	231
Biomarkers for Assessment of Efficacy of Cancer Therapy	232
Biomarkers of Angiogenesis for Developing Antiangiogenic Therapy	234
Biomarkers of Drug Resistance in Cancer	237
Biomarkers of Radiation Exposure	238
Role of Biomarkers in Drug Development in Oncology	239
Molecular Imaging of Tumor as a Guide to Drug Development . .	239
Biomarkers in Plucked Hair for Assessing Cancer Therapy	241
Molecular Targets of Anticancer Drugs as Biomarkers	241
Safety Biomarkers in Oncology Studies	242
Role of Biomarkers in Phase I Clinical Trials of Anticancer Drugs .	242
Biomarkers According to Location/Type of Cancer	243
Bladder Cancer Biomarkers	243
Brain Cancer Biomarkers	244
Breast Cancer Biomarkers	250
Cervical Cancer Biomarkers	268
Gastrointestinal Cancer Biomarkers	269
Head and Neck Cancer	275
Leukemia Biomarkers	276
Liver Cancer Biomarkers	281
Lung Cancer Biomarkers	282

Malignant Pleural Mesothelioma	291
Melanoma Biomarkers	292
Nasopharyngeal Carcinoma Biomarkers	294
Oral Cancer Biomarkers	296
Ovarian Cancer Biomarkers	297
Pancreatic Cancer Biomarkers	302
Prostate Cancer	306
Renal Cancer Biomarkers	317
Thyroid Cancer Biomarkers	320
Role of the NCI in Biomarkers of Cancer	322
Cancer Genetic Markers of Susceptibility Project	322
Oncology Biomarker Qualification Initiative	322
Role of NCI in Cancer Biomarker Development and Validation	323
Future Prospects for Cancer Biomarkers	324
Cancer Biomarker Research at Academic Institutions	324
Future Prospects and Challenges in the Discovery of Cancer Biomarkers	325
7 Biomarkers of Disorders of the Nervous System	327
Introduction	327
Discovery of Biomarkers of Neurological Disorders	327
Biomarker Identification in the CSF Using Proteomics	328
Biomarker Identification in the CSF Using Lipidomics	329
Cerebral Microdialysis for the Study of Biomarkers of Cerebral Metabolism	329
Detection of Protein Biomarkers of CNS Disorders in the Blood	330
Brain Imaging for Detection of Biomarkers	330
Data Mining for Biomarkers of Neurological Disorders	331
Antibodies as Biomarkers in Disorders of the Nervous System	331
Biomarkers of Neural Regeneration	331
Biomarkers of Disruption of Blood-Brain Barrier	332
Biomarkers of Neurotoxicity	333
Glial Fibrillary Acidic Protein as Biomarker of Neurotoxicity	333
Single-Stranded DNA as a Biomarker of Neuronal Apoptosis	334
Biomarkers of Neurodegenerative Disorders	334
Biomarkers of Alzheimer Disease	335
Biomarkers of Parkinson Disease	354
Biomarkers of Huntington Disease	358
Biomarkers of Wilson Disease	360
Biomarkers of Amyotrophic Lateral Sclerosis	360
Biomarkers of Dementia in HIV-1-Infected Patients	364
Biomarkers of Prion Diseases	364
Biomarkers of Multiple Sclerosis	365
Antibodies in Multiple Sclerosis	366
T Cells as Biomarkers of Multiple Sclerosis	368

Matrix Metalloproteinases as Biomarkers in Multiple Sclerosis	369
Gelsolin as a Biomarker of Multiple Sclerosis	369
Gene Expression Profiling of Biomarkers in Multiple Sclerosis	369
Serum Proteomic Pattern Analysis in Multiple Sclerosis	370
Biomarkers of Remyelination and Repair	370
Biomarkers of Response to Therapy of Multiple Sclerosis	371
Concluding Remarks and Future Perspective of Biomarkers of Multiple Sclerosis	371
Biomarkers of Stroke	372
Biomarkers of Intracerebral Hemorrhage	374
Biomarkers of Hypoxic Brain Damage	374
Brain Natriuretic Peptide as a Biomarker of Cardioembolic Stroke	375
Brain Lactate and N-Acetylaspartate as Biomarkers of Stroke	375
Intercellular Adhesion Molecule 1 as Biomarker of Ischemic Stroke	375
Lp-PLA2 and CRP as Biomarkers of Stroke	376
Neuroserpin Polymorphisms as a Biomarker of Stroke	376
NMDA Receptors as Biomarkers of Excitotoxicity in Stroke	376
Nucleosomes as Biomarkers of Stroke	377
PARK7 and Nucleoside Diphosphate Kinase A as Biomarkers of Stroke	377
Visinen-Like Protein 1	378
Gene Expression in Blood Following Ischemic Stroke	378
Future Prospects of Biomarkers of Stroke	379
Biomarkers of Traumatic Brain Injury	380
Technologies for Identification of Biomarkers of TBI	381
Biomarkers of TBI	383
Biomarkers of Inflicted TBI in Infants	384
Clinical Applications of Biomarkers of TBI	385
Biomarkers of CNS Infections	385
Biomarkers of CNS HIV Infection	386
Biomarkers of Bacterial Meningitis	386
Biomarkers of Epilepsy	387
Genetic Epilepsies	387
Biochemical Markers of Epilepsy	387
Imaging Biomarkers of Epilepsy	388
Biomarkers of Normal Pressure Hydrocephalus	388
Biomarkers of Retinal Disorders	389
Biomarkers of Age-Related Macular Degeneration	389
Biomarkers of Autism	390
Biomarkers of Sleep Disorders	391
Biomarker of Excessive Daytime Sleepiness	391
Biomarkers of Obstructive Sleep Apnea	392
Biomarkers of Restless Legs Syndrome	392
Biomarkers of Psychiatric Disorders	393

Biomarkers of Depression	393
Biomarkers of Psychosis	394
Biomarkers of Schizophrenia	394
8 Biomarkers of Cardiovascular Disorders	397
Introduction	397
Epidemiology of Cardiovascular Disease	397
Biomarkers of Cardiovascular Diseases	398
Genetic Biomarkers of Cardiovascular Disorders	399
Methods for Identification of Cardiovascular Biomarkers	401
Application of Proteomics for Biomarkers of Cardiovascular Disease	401
Detection of Biomarkers of Myocardial Infarction in Saliva by a Nanobiochip	402
Metabolomic Technologies for Biomarkers of Myocardial Ischemia	402
Imaging Biomarkers of Cardiovascular Disease	403
Applications of Biomarkers of Cardiovascular Disease	404
Biomarkers for Ischemic Heart Disease and Myocardial Infarction	404
Biomarkers of Congestive Heart Failure	409
Biomarkers for Atherosclerosis	413
Biomarkers of Risk Factors for Coronary Heart Disease	416
Biomarkers for Pulmonary Arterial Hypertension	419
Genetic Biomarkers for Cardiovascular Disease	420
Multiple Biomarkers for Prediction of Death from Cardiovascular Disease	425
Role of Biomarkers in the Management of Cardiovascular Disease	426
Role of Biomarkers in the Diagnosis of Myocardial Infarction	426
Role of Biomarkers in the Prevention of Cardiovascular Disease	426
Molecular Signature Analysis in Management of Cardiovascular Diseases	427
C-Reactive Protein as Biomarker of Response to Statin Therapy	427
Role of Circulating Biomarkers and Mediators of Cardiovascular Dysfunction	428
Use of Biomarkers in the Management of Peripheral Arterial Disease	429
Use of Biomarkers in the Management of Hypertension	429
Use of Protein Biomarkers for Monitoring Acute Coronary Syndromes	429
Use of Multiple Biomarkers for Monitoring of Cardiovascular Disease	430
Future Prospects for Cardiovascular Biomarkers	431
Cardiovascular Biomarker Consortium	431
Systems Approach to Biomarker Research in Cardiovascular Disease	432

9 Biomarkers and Personalized Medicine	433
Introduction	433
Pharmacogenetics	434
Biomarkers and Pharmacogenetics	434
Pharmacogenomics	436
Pharmacoproteomics	436
Single-Cell Proteomics for Personalized Medicine	437
Role of Biomarkers in Development of Personalized Drugs	438
Use of Biomarkers for Developing MAb Therapy in Oncology	438
Biobanking, Biomarkers, and Personalized Medicine in EU	438
Expression Signatures as Diagnostic/Prognostic Tools	440
Biomarkers for Monitoring Response to Therapy	440
Drug Rescue by Biomarker-Based Personalized Medicine	441
Future Role of Biomarkers in Personalized Medicine	442
10 Regulatory Issues	443
Introduction	443
Biomarker Validation	443
FDA Criteria for a Valid Biomarker	444
Role of NIST in Validation of Cancer Biomarkers	445
Quality Specifications for BNP and NT-proBNP as Cardiac Biomarker Assays	446
FDA Perspective of Biomarkers in Clinical Trials	447
FDA and Predictive Medicine	449
Biomarkers and FDA's Voluntary Genomic Data Submission	449
Role of Imaging Biomarkers in Approval of Drugs	450
FDA Critical Path Initiative and Biomarker R&D	451
FDA Consortium Linking Genetic Biomarkers to Serious Adverse Events	451
Oncology Biomarker Qualification Initiative	452
Critical Path Initiative	453
From Validated Biomarker Assay to a Clinical Laboratory Diagnostic	456
Fast Path Programs	456
Need for a Single Federal Agency to Oversee Biomarker Field	457
References	459
Subject Index	487